TY - JOUR
T1 - Aromatase inhibitors
T2 - Rationale and use in breast cancer
AU - Osborne, Cynthia
AU - Tripathy, Debu
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005
Y1 - 2005
N2 - Considerable data implicate estrogens in breast cancer carcinogenesis and progression. In the postmenopausal woman, estrogens are produced in breast tissues and many other sites throughout the body when androgen precursors are converted into estrogens via the enzyme aromatase. Inhibition of this enzyme with aromatase inhibitors (AIs) has demonstrated reductions in systemic as well as intratumoral estrogens. These drugs have now been utilized in large phase 3 randomized trials and have led to greater improved clinical benefit than the "gold standard," tamoxifen. Questions remain about the long-term side effects and safety profile of AIs. They are associated with increasing incidence of osteoporosis and bone fractures. Nevertheless, AIs add to our armamentarium for therapy and possible prevention of breast cancer.
AB - Considerable data implicate estrogens in breast cancer carcinogenesis and progression. In the postmenopausal woman, estrogens are produced in breast tissues and many other sites throughout the body when androgen precursors are converted into estrogens via the enzyme aromatase. Inhibition of this enzyme with aromatase inhibitors (AIs) has demonstrated reductions in systemic as well as intratumoral estrogens. These drugs have now been utilized in large phase 3 randomized trials and have led to greater improved clinical benefit than the "gold standard," tamoxifen. Questions remain about the long-term side effects and safety profile of AIs. They are associated with increasing incidence of osteoporosis and bone fractures. Nevertheless, AIs add to our armamentarium for therapy and possible prevention of breast cancer.
KW - Estrogen deprivation
KW - Hormonal manipulation
UR - http://www.scopus.com/inward/record.url?scp=14544303729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14544303729&partnerID=8YFLogxK
U2 - 10.1146/annurev.med.56.062804.103324
DO - 10.1146/annurev.med.56.062804.103324
M3 - Review article
C2 - 15660504
AN - SCOPUS:14544303729
SN - 0066-4219
VL - 56
SP - 103
EP - 116
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -